Trial Profile
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Ribociclib (Primary) ; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 16 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 16 Oct 2023 Planned primary completion date changed from 30 Nov 2023 to 29 Nov 2024.
- 19 Jul 2023 Results of pooled data from NCT01898845, NCT01237236, NCT01872260, NCT01958021,NCT02422615, NCT02278120 to determine PK, safety and efficacy of Ribociclib in combination with endocrine therapy (ET) presented in the Journal of Clinical Pharmacology